We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

On January 9 th, 2025 Intellia Therapeutics posted a press release titled “Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement ...

Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities ...

The inducement grant consisted of time-based restricted stock units ("RSUs”) for 21,863 shares of Intellia's common stock, ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

Intellia Therapeutics has said it will reduce its ... its first patients in MAGNITUDE-2 before the end of March. In other news, Intellia announced that chief scientific officer Laura Sepp-Lorenazo ...

The complete 8-K filing and updates can be accessed on Intellia Therapeutics’ official website. This news release may contain forward-looking statements subject to risks and uncertainties ...

https://www.tipranks.com/news/the-fly/hookipa-pharma-announces-enrollment-completion-of-phase-1b-hb-500-trial BMO Capital lowered the firm’s price target on ...

Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also ...

Intellia Therapeutics shifts focus to NTLA-2002 for hereditary angioedema and nex-z for ATTR amyloidosis, advancing Phase 3 trials in 2025. Strategic reorganization includes a 27% workforce ...